Renowned for its ‘in-depth understanding’ of the healthcare and life sciences industries, Fangda Partners excels in licensing transactions, capital markets, and private equity investments. Josh Shin leads the practice, offering significant expertise in regulatory issues related to clinical trials, R&D, and patient-centric transformations. Diana Li is sought after by PE/VC funds and international pharmaceutical companies for acquisitions and investments in medical device, pharmaceutical, and medical laboratory firms. Meanwhile, Henry He specialises in cross-border transactions, including product and technology in- and out-licensing.

Offering a ‘deep familiarity with the life sciences and healthcare fields,’ Global Law Office is a popular choice for start-ups, multinational corporations, listed companies, and government institutions in the pharmaceuticals, medical devices, and biotech fields. Spearheaded by Alan Zhou and Michael Yu, the team supports clients in daily operations, IP protection, compliance, and investment matters. Jerry Liu assists investors and biopharma companies, and Charlene Huang‘s experience includes advising on cell therapy, medical AI, and digital healthcare projects. Coco Fan brings extensive expertise in compliance and transactions within the healthcare industry, and Rae Zhang supports pharmaceutical companies with drug promotion, clinical trials, and data protection.

King & Wood Mallesons is a ‘trusted partner’ for Chinese and international clients across the pharmaceutical, biotech, hospital, and medical devices sectors, as well as for investors in these industries. Led by Jianwen Huang, the group offers a wide range of legal services, including M&A, IPOs, compliance, and licensing. Yuanyuan Zhu and Ting Liu support healthcare and pharmaceutical clients with anti-commercial bribery investigations and establishing compliance systems. Mark Zhang brings extensive expertise in M&A, clinical trials, and drug licensing transactions. Fan Yang departed the firm in February 2024.

Praised for being ‘professional and responsive,’ Zhong Lun Law Firm’s capabilities include financing, domestic and overseas IPOs, and medical products regulation, as well as compliance, licensing, and intellectual property issues. Overseeing the department are Changyu Fu, who brings experience in dispute resolution and anti-trust, and Helen Cheng. Dongmei Wang leads the healthcare team, while Jim Qiu and Shaun Gao direct the pharmaceuticals and life sciences group. Yuru Zuo is sought after by pharmaceutical companies for her product liability, clinical trials, and approval of human legacy knowledge, and Qi Lan stands out for her patent prosecution, invalidation, and litigation expertise.

Haiwen & Partners is sought after by pharmaceutical, biotech, Chinese medicine, and cosmetics clients on a broad array of matters arising from the entire company and product life cycle. With healthcare and life sciences specialist Tina Wu at the helm, the firm is able to advise on licensing, clinical research regulatory issues, market access strategies, and data privacy. Rui Feng and Wenzhen Dai contribute to the group’s M&A expertise, and Frank Wang is experienced in intellectual property matters.

With a ‘strong team of lawyers specialising in life sciences and healthcare,’ Han Kun Law Offices has extensive experience supporting pharmaceutical and healthcare companies with their compliance, regulatory, and commercial needs. Led by Yinshi Cao, the team is also adept at representing private equity and venture capital funds with their investments in the sector. Aaron Gu stands out for his deep industry expertise, including clinical trials, drug licensing, biosecurity, and GxP compliance knowledge. Clients instruct Chaoying (Charles) Li for his public and private financings, M&A, and IP protection expertise. Aaron Zhou supports multinational and domestic companies with licensing in- and out-transactions, research collaboration, and manufacturing services agreements.

JunHe LLP supports healthcare and life sciences clients across the full cycle of their businesses, from incubation, applying for licenses, and seed funding to M&A, IPO, and restructuring. Jointly led by Xudong Tao, Feng (Frank) Zhou, Zhaohui (Zoe) Wang, and Jian (James) Zhu, the group also advises on the entire industry chain of medical products, covering drug development, patents, clinical trials, and commercialisation. Corporate M&A expert Ning Liu is a key member of the team.

AnJie Broad Law Firm handles a wide range of matters in the pharmaceutical, medical devices, internet healthcare, and biotech spaces, including financings, licensing transactions, IP due diligence, and anti-trust compliance. Hang Cai is a popular choice for private equity and venture capital firms, and Nick Liu excels in disputes involving patents, trademarks, and trade secrets. Long Gu’s practice encompasses cross-border equity transfers, license-in and license-out deals. and collaboration projects, while Ying Song is an anti-monopoly and unfair competition expert.

DaHui Lawyers regularly advises on market entry, intellectual property issues, corporate transactions, and disputes within the pharmaceutical and life sciences industry. Leading the practice is Richard Ma, who is experienced in assisting Chinese and multinational enterprises with financings, M&A, and restructuring, as well as with regulatory and compliance matters. Julia Dai offers expertise in equity and debt capital market transactions, and Joanna Jiang’s practice includes data compliance and cross-border investment transactions.

Notable for its China-wide offering, Dacheng features life science and healthcare experts across branches including Beijing, Shanghai, Nanjing, and Chongqing. The group supports businesses with matters such as investments, regulatory compliance for clinical trials and drug research, patent protection, and contractual disputes. Tao Shen excels in legal risk assessment and prevention in the medical and health industry, and Andy (Xin) Wang is praised by clients for his ‘practical’ advice in the field. Fu Chen brings deep knowledge in medical intellectual property protection and litigation.

As Baker McKenzie’s joint operation partner, FenXun Partners is regularly instructed by global pharmaceutical, healthcare, and medical device companies on their cross-border work. Practice leader Vivian Wu specialises in China-related regulatory and compliance matters, with a focus on data protection and anti-corruption issues. Hong Zhang brings experience in M&A, joint ventures, and private equity investments, while Yilan Yang concentrates on intellectual property licensing, trademark, and patent issues faced by healthcare and cosmetics clients.

Jingtian & Gongcheng boasts ‘deep insights and connections in the medical field’ and offers specialised services including technology licensing, commercialisation, medical information data compliance, and clinical trial registration. The group is particularly renowned for its track record in completing Hong Kong IPO projects. Hanshuo Zhou brings experience in license-in and license-out transactions, drug registration, and M&A. Capital markets and investment expert Boija Zhao concentrates on the life sciences and healthcare sector, supporting pharmaceutical companies across the entire product and business lifecycle.

The healthcare and life sciences team at Llinks Law Offices is comprised of lawyers with deep experience in M&A, FDI, compliance, and commercial matters, and works closely with the firm’s capital markets, dispute resolution, and asset management practice groups. Led by Nicholas Lou and Grant Chen, the team is instructed by clients in the investment, internet healthcare services, medical devices, and pharmaceutical industries. David Yu contributes cross-border investment expertise, and Xun Yang is knowledgeable about intellectual property, outsourcing, and information security.

The ‘very professional’ team at Shihui Partners offers rich expertise in pharmaceutical compliance systems, licensing transactions, the regulation of new products, and investments. Miranda Jiang, Zan Zhu, and Xiaomei Li are experienced in capital markets, private equity, and venture capital, while Jing Lu is ‘an outstanding partner in the compliance team’ who is regularly instructed by foreign pharmaceutical companies.

Clients in the medical devices, biotech, hospital, and investment spaces turn to Tian Yuan Law Firm for its ‘wide range of knowledge’ in commercial and compliance issues. Juanjuan Song directs the healthcare practice, offering significant expertise in corporate investment and mergers. The group benefits from Yan Liu’s capital markets experience, Jiayun Xie’s private equity financing specialism, and Aihua Xiao’s bankruptcy reorganisation focus.

With Jing Pang at the helm, AllBright Law Offices provides services including M&A, domestic and overseas listings, compliance, and dispute resolution to a range of pharmaceutical and medical companies. Congjun Wen, Chengwei Pang, and Zhengchun Yu are key members of the team, each bringing deep experience in private equity financing and investment.

Commerce & Finance Law Offices has a strong track record representing biotech and pharmaceutical companies on their listings, especially Chapter 18A listings in the Hong Kong market. Meng Zhang is experienced in private equity financing and M&A by foreign investors. Key individuals in the healthcare capital markets practice include Wei Sun, Xiaoman Zhang, and Bo Wang.

Jincheng Tongda & Neal’s medicine and healthcare industry group, led by Guodong Zhang, advises on the establishment of pharmaceutical companies, patent applications, anti-commercial bribery compliance, and M&A. The team includes dispute resolution specialist Zhixue Lin, whose expertise includes patent and trademark disputes, as well as healthcare law expert Huan An, who is instructed by health administrative organs, medical institutions, and military units.

ZSK Attorneys-at-Law provides ‘expert guidance’ to domestic and multinational clients in the life sciences and healthcare industry, including assistance with licensing agreements, anti-corruption policies, and building compliance systems. Yue Peng directs the group, bringing a wealth of experience advising pharmaceutical and biotech companies on commercialisation, clinical trials, and financing transactions.